Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CTKB Cytek Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: CTKB
Price (delayed)
$3.79
Market cap
$485.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.05
Enterprise value
$395.35M
Highlights
The net income has soared by 50% year-on-year and by 41% since the previous quarter
The debt has contracted by 23% YoY and by 4.3% from the previous quarter
Cytek Biosciences's EPS has plunged by 100% from the previous quarter but it has increased by 44% YoY
The quick ratio has contracted by 12% YoY and by 4.9% from the previous quarter
The gross margin has contracted by 2.3% YoY
Key stats
What are the main financial stats of CTKB
Market
Valuations
Earnings
Shares outstanding
128.1M
Market cap
$485.49M
Enterprise value
$395.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.23
Price to sales (P/S)
2.47
EV/EBIT
N/A
EV/EBITDA
39.42
EV/Sales
1.97
Revenue
$200.45M
Gross profit
$111.11M
Operating income
-$20.52M
Net income
-$6.02M
EBIT
-$461,000
EBITDA
$10.03M
Free cash flow
$21.94M
Per share
Balance sheet
Liquidity
EPS
-$0.05
EPS diluted
-$0.05
Free cash flow per share
$0.17
Book value per share
$3.07
Revenue per share
$1.53
TBVPS
$3.54
Total assets
$499.5M
Total liabilities
$103.76M
Debt
$8.6M
Equity
$395.74M
Working capital
$328.78M
Debt to equity
0.02
Current ratio
5.86
Quick ratio
5
Net debt/EBITDA
-8.99
Margins
Efficiency
Dividend
EBITDA margin
5%
Gross margin
55.4%
Net margin
-3%
Operating margin
-10.2%
Return on assets
-1.2%
Return on equity
-1.5%
Return on invested capital
-0.2%
Return on capital employed
-0.1%
Return on sales
-0.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTKB stock price
How has the Cytek Biosciences stock price performed over time
Intraday
1.61%
1 week
2.43%
1 month
12.46%
1 year
-39.55%
YTD
-41.6%
QTD
-5.49%
Financial performance
How have Cytek Biosciences's revenue and profit performed over time
Revenue
$200.45M
Gross profit
$111.11M
Operating income
-$20.52M
Net income
-$6.02M
Gross margin
55.4%
Net margin
-3%
The net margin has soared by 52% YoY and by 40% from the previous quarter
The net income has soared by 50% year-on-year and by 41% since the previous quarter
The operating margin has grown by 29% YoY and by 14% from the previous quarter
CTKB's operating income is up by 26% YoY and by 13% from the previous quarter
Price vs fundamentals
How does CTKB's price correlate with its fundamentals
Growth
What is Cytek Biosciences's growth rate over time
Valuation
What is Cytek Biosciences stock price valuation
P/E
N/A
P/B
1.23
P/S
2.47
EV/EBIT
N/A
EV/EBITDA
39.42
EV/Sales
1.97
Cytek Biosciences's EPS has plunged by 100% from the previous quarter but it has increased by 44% YoY
CTKB's price to book (P/B) is 39% lower than its last 4 quarters average of 2.0
Cytek Biosciences's equity has increased by 2.7% from the previous quarter
The P/S is 38% below the last 4 quarters average of 4.0
The company's revenue rose by 3.9% YoY
Efficiency
How efficient is Cytek Biosciences business performance
Cytek Biosciences's ROS has soared by 98% YoY and by 97% from the previous quarter
The return on invested capital has surged by 97% since the previous quarter and by 97% year-on-year
Cytek Biosciences's return on assets has surged by 50% YoY and by 43% QoQ
Cytek Biosciences's return on equity has increased by 48% YoY and by 42% QoQ
Dividends
What is CTKB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTKB.
Financial health
How did Cytek Biosciences financials performed over time
CTKB's current ratio is down by 16% year-on-year and by 6% since the previous quarter
The quick ratio has contracted by 12% YoY and by 4.9% from the previous quarter
The debt is 98% less than the equity
The debt to equity has contracted by 33% YoY
The debt has contracted by 23% YoY and by 4.3% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.